普健生物(武汉)科技有限公司

首页 产品目录 产品目录(简版) 公司动态 企业认证 企业体检 公司相册 联系我们

武汉艾必赛生物有限公司推荐Anti-HPV16 L2/Minor capsid protein L2 Antibody (MAb24B) ,精品抗体

发布人:普健生物(武汉)科技有限公司

发布日期:2026/1/19 14:29:56

链接:https://www.abinscience.cn/product/34/15299.html


 

名称:Anti-HPV16 L2/Minor capsid protein L2 Antibody (MAb24B)

 

货号:VK658013

 

种属反应性:Human papillomavirus type (HPV16, HPV18, HPV31, HPV33, HPV35, HPV51, HPV52, HPV58)

 

宿主:Human

 

纯度:>95% as determined by SDS-PAGE.

 

克隆性:Monoclonal

 

同种型:IgG1, kappa

 

应用:WB

 

靶点:Minor capsid protein L2, L2

 

用途范围:仅用于科研

 

储存:Use  a manual defrost freezer and avoid repeated freeze-thaw cycles. Store  at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C  long term.

 


产品介绍:

Anti-HPV16 L2/Minor capsid protein L2 Monoclonal Antibody (MAb24B) 是一种人源化单克隆抗体,由能够特异性识别人乳头瘤病毒16 型次要衣壳蛋白L2 的高变区(VH/VL)与human IgG1 Fc 片段融合而成。这种结构设计使抗体在结合HPV16 L2 蛋白时兼具高特异性和高亲和力,同时借助IgG1 Fc 片段的稳定性优势,显著提升了Western Blot 等免疫检测实验的灵敏度与重复性。abinScience产品具有亲和力高,灵敏度高,特异性好,稳定性强等优势。


 

产品购买联系方式:027-87433958/17302791434

 

邮箱:info@abinscience.com

新闻图片1


 

参考文献:

The  high risk HPV16 L2 minor capsid protein has multiple transport signals  that mediate its nucleocytoplasmic traffic. PMID: 22154072

 

The l2 minor capsid protein of human papillomavirus type 16 interacts with a network of nuclear import receptors. PMID: 15507604

 

Efficient Inhibition of Human Papillomavirus Infection by L2 Minor Capsid-Derived Lipopeptide. PMID: 31387913

 

Human Papillomavirus Type 16 L2 Gene Sequence Variation Analysis in Indonesian Cervical Cancer Specimens. PMID: 35763643

 

A  papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes  induces cross-neutralizing antibodies to HPV11. PMID: 17239496

 

The evolving field of human papillomavirus receptor research: a review of binding and entry. PMID: 23536685

 

Factors influencing subcellular localization of the human papillomavirus L2 minor structural protein. PMID: 16257028

 

HPV16  entry requires dynein for minus-end transport and utilizes kinesin  Kif11 for plus-end transport along microtubules during mitosis. PMID:  39629998

 

Chimeric  human papillomavirus type 16 (HPV-16) L1 particles presenting the  common neutralizing epitope for the L2 minor capsid protein of HPV-6 and  HPV-16. PMID: 12857908

 

Cross-neutralization potential of native human papillomavirus N-terminal L2 epitopes. PMID: 21346798

 

Direct  binding of retromer to human papillomavirus type 16 minor capsid  protein L2 mediates endosome exit during viral infection. PMID: 25693203

 

The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PMID: 22927980

 

Capsid  display of a conserved human papillomavirus L2 peptide in the  adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine  approach. PMID: 26362430

 

Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV). PMID: 28056100

 

L2  epitope presenting virus-like particles as broad-spectrum vaccine  candidates targeting genus beta human papillomaviruses. PMID: 41333421

 

Vesicular  trafficking of incoming human papillomavirus 16 to the Golgi apparatus  and endoplasmic reticulum requires gamma-secretase activity. PMID:  25227470

 

Inhibition  of Langerhans cell maturation by human papillomavirus type 16: a novel  role for the annexin A2 heterotetramer in immune suppression. PMID:  24719459

 

Human  Papillomavirus 16 L2 Recruits both Retromer and Retriever Complexes  during Retrograde Trafficking of the Viral Genome to the Cell Nucleus.  PMID: 33177206

 

Cryoelectron Microscopy Maps of Human Papillomavirus 16 Reveal L2 Densities and Heparin Binding Site. PMID: 28065506

 

Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras. PMID: 23924054

 

Nuclear import strategies of high risk HPV16 L1 major capsid protein. PMID: 11971900

 

Efficient delivery of DNA vaccines using human papillomavirus pseudovirions. PMID: 20668481

 

The  cellular endosomal protein stannin inhibits intracellular trafficking  of human papillomavirus during virus entry. PMID: 29058661

 

A  chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against  oncogenic alpha-7 human papillomavirus types. PMID: 25790098

 

Broad  Cross-Protection Is Induced in Preclinical Models by a Human  Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.  PMID: 27147749

 

Vaccination  with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden  protection against HPV infection. PMID: 20434552

 

Transient  expression of Human papillomavirus type 16 L2 epitope fused to N- and  C-terminus of coat protein of Potato virus X in plants. PMID: 22357210

 

Chimeric  papillomavirus virus-like particles elicit antitumor immunity against  the E7 oncoprotein in an HPV16 tumor model. PMID: 9465097

 

Optimizing a Human Papillomavirus Type 16 L1-Based Chimaeric Gene for Expression in Plants. PMID: 30062095




详情请咨询 abinScience 亚洲区官方子公司 —— 武汉艾必赛生物技术有限公司


官方网址:【中文】https://www.abinscience.cn

 【英文】https://www.abinscience.com




武汉艾必赛生物技术有限公司成立于 2023 年,是 abinScience 在亚洲地区设立的官方全资子公司,全面负责 abinScience 品牌在亚太市场的科研试剂推广、销售及技术支持工作。

依托严格的产品研发体系和国际化的质量管理标准,武汉艾必赛与  AtaGenix、ProteoGenix  等知名品牌保持长期战略合作,现已构建起涵盖抗体、重组蛋白、工具酶、试剂盒、实验耗材在内的多品类供应体系,面向区域内科研机构、高校实验室与生物医药企业,提供稳定、高效、可信赖的产品与服务。



核心业务覆盖:

✅ 抗体产品(单抗、多抗、重组抗体等)

✅ 蛋白与多肽试剂(标签蛋白、功能蛋白等)

✅ 分子与细胞实验相关耗材

✅ 定制化研发服务(蛋白表达、抗体定制、亲和力成熟等)

✅ 科研供应链整合与项目配套支持

武汉艾必赛始终秉持“Empowering Bioscience Discovery”的理念,为亚太地区的生命科学研究持续注入高质量动能。

 

027--87433958.jpg

相关新闻资讯

从Rocatinlimab全球临床终止,看OX40靶点的基础研究边界与转化挑战

2026/04/20

2026年3月3日,日本协和麒麟(Kyowa Kirin)发布官方公告,宣布立即终止OX40靶向单克隆抗体Rocatinlimab的全部全球临床试验。此前,该药物的全球合作开发方安进(Amgen),已于2026年2月以战略优先级调整为由,将Rocatinlimab的全球开发权全部退回协和麒麟。作为全球推进至多项III期临床的OX40阻断型抗体,Rocatinlimab核心适应症覆盖中重度特

abinScience助力揭秘老牌中药脑震宁通过槲皮素-叶黄素-HMOX1轴精准抑制反复脑震荡后神经元铁死亡

2026/04/15

创伤性脑损伤(TBI)全球每年影响约6900万人,其中轻度创伤性脑损伤(mTBI)占比高达80%-90%。反复轻度创伤性脑损伤(rmTBI)作为常见类型,可引发头痛、抑郁、记忆缺陷等持续性症状,且显著增加帕金森病、阿尔茨海默病等神经退行性疾病的发病风险。目前,rmTBI 的病理机制尚未完全明确,临床缺乏治疗手段。铁死亡是一种铁依赖的程序性细胞死亡,以脂质过氧化物和活性氧(ROS)积累为特征,其

甲亢与 Graves 病:从病理机制到新一代免疫靶向疗法

2026/04/15

甲状腺功能亢进症(简称甲亢)(Hyperthyroidism)是一种常见的内分泌疾病,指甲状腺激素(T4和T3)分泌过多,导致机体代谢率升高和新陈代谢加速的临床综合征。最常见类型为Graves病(GD),占所有甲亢病例的80-90%。GD是一种自身免疫性疾病,由促甲状腺激素受体(TSHR)刺激性自身抗体(TRAb)引起,导致甲状腺过度分泌激素。其他原因包括毒性结节性甲状腺肿、亚急性甲状腺炎等。全球